DCTH Delcath stock news
On October 19, 2026, Delcath Systems, Inc. (Nasdaq: DCTH) announced upcoming presentations on its clinical development pipeline at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23–27, 2026, in Madrid, Spain. The company will showcase a trial--in--progress poster for DELUMA, an open--label, randomized Phase 2 study evaluating melphalan hepatic delivery system (HDS) induction followed by standard therapy versus standard therapy alone in patients with liver--dominant metastatic breast cancer, alongside updates during a "Meet the Investigators" session covering both DELUMA and the Del--Liver Phase 2 trial in metastatic colorectal cancer. Delcath also highlighted published independent data from St. Vincent's University Hospital assessing percutaneous hepatic perfusion with CHEMOSAT in metastatic uveal melanoma, which demonstrated an objective response rate of 66.7% and a median overall survival of 28 months.